| abstract |
The present invention provides a heteroarylcarboxamide derivative as a plasma kallikrein inhibitor. The present invention has general pharmacological properties, particularly plasma kallikrein inhibitors, general formula I, wherein D1-D3, A, R1, R2, Y and n are claimed. As defined in item 1). The compounds are suitable for the treatment and prevention of diseases that can be affected by inhibition of plasma kallikrein, such as diabetic complications, especially the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. I [Selection figure] None |